CNS Pharmaceutical

Name

CNS Pharmaceutical

Legal name

CNS Pharmaceuticals, Inc.

Website

https://cnspharma.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals / Oncology Drug Development

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Oncology & Hematology Pharmaceuticals (HLAIAAAC), Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Oncology drug development
• Glioblastoma treatment
• Blood-brain barrier therapeutics
• Clinical-stage biopharmaceuticals
• CNS cancer pipeline

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Pre-revenue biotechnology company. Revenue generation is contingent on successful clinical development, regulatory approval, and commercialization of drug candidates (Berubicin and TPI 287) for glioblastoma and other CNS cancers. The company is also exploring out-licensing opportunities for legacy programs.
2. Public and Private Financings: The company raises capital through registered direct offerings, private placements, and public offerings of common stock and warrants. Recent financings include: $22.5M private placement (May 2026), $3M registered direct offering (October 2024), $1.37M registered direct offering (June 2024), $6M public offering (December 2022), $11.5M private placement (January 2022).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

CNS Pharmaceuticals is a pre-revenue, clinical-stage biotechnology company developing novel therapeutics for brain cancers, primarily glioblastoma multiforme (GBM). Its pipeline includes two drug candidates — Berubicin (a second-generation anthracycline topoisomerase II inhibitor) and TPI 287 (an abeotaxane microtubule inhibitor) — both engineered to cross the blood-brain barrier. Following a March 2026 strategic pivot, the company is now focused on acquiring or in-licensing differentiated neurology and oncology assets while exploring out-licensing of legacy glioblastoma programs.

Product overview

CNS Pharmaceuticals is a biotechnology company focused on building a pipeline of innovative therapies in neurology and oncology. The company has undergone a strategic transformation, pivoting from its legacy glioblastoma program to acquiring or in-licensing preclinical and clinical-stage assets in neurology and oncology. The legacy pipeline includes Berubicin (a topoisomerase II inhibitor for glioblastoma) and TPI 287 (an abeotaxane for brain malignancies), both of which are being explored for out-licensing as they no longer align with the forward-looking growth strategy. The company also maintains an Expanded Access Program for compassionate use of investigational drugs.

Differentiator

Problem solved

Functional benefit

Products and services

• Berubicin A novel, synthetic, second-generation anthracycline-based topoisomerase II inhibitor engineered to circumvent the blood-brain barrier (BBB) and overcome multi-drug resistance (MDR) for the treatment of glioblastoma multiforme (GBM). Has been administered to humans in 4 clinical trials. The company is currently exploring out-licensing of this legacy asset to pharmaceutical partners.
• TPI 287 A small molecule belonging to the taxane diterpenoid (taxoid) family (abeotaxane class). Novel synthetic microtubule inhibitor that disrupts cancer cell growth by destabilizing microtubules. Unlike other taxanes, TPI 287 is not a substrate for efflux pumps (including PgP) at the BBB, allowing high brain concentrations. Tested in over 350 patients across multiple trials. The company is exploring out-licensing of this legacy asset.
• Expanded Access Program Compassionate use program that allows physicians to request access to investigational drugs for seriously ill patients who have no comparable alternative therapies and cannot enroll in clinical trials. Currently on hold due to supply constraints.

Quantifiable outcome

• Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints in late-stage global clinical trial, with favorable safety profile including absence of anthracycline-related cardiotoxicity
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered minor.

• Society of NeuroOncology (SNO)minorStrategic or Co-development Partner · 11 November 2025CNS Pharmaceuticals had three abstracts accepted for poster presentations at the 2025 Society of NeuroOncology (SNO) 30th Annual Meeting in Honolulu, HI. Presentations included clinical data on TPI 287 and its potential in treating brain cancers like glioblastoma.
• Continental Stock Transfer & TrustminorOthersCompany's transfer agent responsible for share registry, stock transfer services, and shareholder record-keeping. Located at 1 State Street, 30th Floor, New York, NY 10004. Contact: 800-509-5586.
• MaloneBailey, LLPminorOthersCNS Pharmaceuticals' independent auditor responsible for annual financial statement audits and financial reporting compliance.
• ArentFox Schiff LLPminorOthersCNS Pharmaceuticals' outside legal counsel providing legal representation for corporate matters, securities, and regulatory compliance.
• JTC Team LLCminorOthersWebsite hosting provider for CNS Pharmaceuticals' corporate website (www.cnspharma.com). Located at 1110 Harrison St, Frenchtown, NJ 08825.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Plus Therapeutics: Clinical-stage oncology company developing targeted radiotherapies for CNS cancers including glioblastoma and leptomeningeal metastases. Direct peer in the CNS oncology drug development space with comparable scale, BBB-focused drug delivery approach, and orphan drug designation strategy.
• Kazia Therapeutics: Australian-listed clinical-stage oncology company with lead asset paxalisib for glioblastoma, which directly competed with CNS Pharmaceuticals' Berubicin in the GBM space. Highly comparable in target indication, clinical stage, orphan drug strategy, and small-cap market positioning - the closest peer by therapeutic focus and business model.
• Kintara Therapeutics: Micro-cap clinical-stage oncology company developing therapies for glioblastoma multiforme. Direct comparable in CNS cancer drug development with similar regulatory strategy (orphan/fast track designations) and parallel clinical positioning against Lomustine comparator, serving the same GBM patient population with similar mechanism-of-action differentiation attempts.
• Diffusion Pharmaceuticals: Clinical-stage biotechnology company developing small-molecule therapies for cancer, with prior lead programs targeting glioblastoma. Direct peer in CNS oncology drug development with similar micro-cap profile, orphan drug approach, and BBB-crossing drug delivery science.

Broad incumbents

• Servier Pharmaceuticals: Mid-size global pharmaceutical company with oncology and CNS therapeutic focus, including brain cancer programs. Comparable as a potential out-licensing partner for legacy CNS assets and as an acquirer of clinical-stage oncology assets that CNS Pharmaceuticals now targets.
• Bristol-Myers Squibb: Global pharmaceutical incumbent with established oncology franchise including CNS cancer treatment assets (e.g., various chemotherapy and immunotherapy programs). Broad incumbent that competes in the same oncology therapeutic space and is a potential out-licensing partner for CNS Pharmaceuticals' legacy programs.

Emerging players

• AnHeart Therapeutics: Clinical-stage oncology company developing next-generation precision therapies for solid tumors including CNS malignancies. Emerging peer in CNS oncology with broader oncology pipeline approach that mirrors CNS Pharmaceuticals' new strategic pivot toward diversified oncology asset acquisition.

Others

• Actinium Pharmaceuticals: Clinical-stage biopharmaceutical company developing targeted radiotherapies for hematologic and solid tumor cancers. Related through CFO Steve O'Loughlin's prior decade-long tenure and overlap in micro-cap oncology drug development space and similar financing patterns through registered direct offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/cns_pharma
• LinkedInlinkedin.com/company/cnspharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CNS Pharmaceutical